Literature DB >> 16424209

Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol.

Kenji Someya1, Yasushi Ami, Tadashi Nakasone, Yasuyuki Izumi, Kazuhiro Matsuo, Shigeo Horibata, Ke-Qin Xin, Hiroshi Yamamoto, Kenji Okuda, Naoki Yamamoto, Mitsuo Honda.   

Abstract

It is believed likely that immune responses are responsible for controlling viral load and infection. In this study, when macaques were primed with plasmid DNA encoding SIV gag and pol genes (SIVgag/pol DNA) and then boosted with replication-deficient vaccinia virus DIs recombinant expressing the same genes (rDIsSIVgag/pol), this prime-boost regimen generated higher levels of Gag-specific CD4+ and CD8+ T cell responses than did either SIVgag/pol DNA or rDIsSIVgag/pol alone. When the macaques were i.v. challenged with pathogenic simian/HIV, the prime-boost group maintained high CD4+ T cell counts and reduced plasma viral loads up to 30 wk after viral challenge, whereas the rDIsSIVgag/pol group showed only a partial attenuation of the viral infection, and the group immunized with SIVgag/pol DNA alone showed none at all. The protection levels were better correlated with the levels of virus-specific T cell responses than the levels of neutralization Ab responses. These results demonstrate that a vaccine regimen that primes with DNA and then boosts with a replication-defective vaccinia virus DIs generates anti-SIV immunity, suggesting that it will be a promising vaccine regimen for HIV-1 vaccine development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424209     DOI: 10.4049/jimmunol.176.3.1784

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  DNA vaccines for HIV: challenges and opportunities.

Authors:  David A Hokey; David B Weiner
Journal:  Springer Semin Immunopathol       Date:  2006-10-10

2.  Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.

Authors:  Yasuyuki Eda; Mari Takizawa; Toshio Murakami; Hiroaki Maeda; Kazuhiko Kimachi; Hiroshi Yonemura; Satoshi Koyanagi; Kouichi Shiosaki; Hirofumi Higuchi; Keiichi Makizumi; Toshihiro Nakashima; Kiyoshi Osatomi; Sachio Tokiyoshi; Shuzo Matsushita; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.

Authors:  Yasuyuki Eda; Toshio Murakami; Yasushi Ami; Tadashi Nakasone; Mari Takizawa; Kenji Someya; Masahiko Kaizu; Yasuyuki Izumi; Naoto Yoshino; Shuzo Matsushita; Hirofumi Higuchi; Hajime Matsui; Katsuaki Shinohara; Hiroaki Takeuchi; Yoshio Koyanagi; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C.

Authors:  Masaru Shimada; Haibin Wang; Motohide Ichino; Takehiro Ura; Nobuhisa Mizuki; Kenji Okuda
Journal:  Gene Ther       Date:  2022-01-06       Impact factor: 5.250

5.  Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys.

Authors:  Shisong Jiang; Robert A Rasmussen; Katrina M Nolan; Fred R Frankel; Judy Lieberman; Harold M McClure; Kristina M Williams; Uma S Babu; Richard B Raybourne; Elizabeth Strobert; Ruth M Ruprecht
Journal:  Vaccine       Date:  2007-08-27       Impact factor: 3.641

6.  Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response.

Authors:  P O Ilyinskii; A B Meriin; V L Gabai; O P Zhirnov; G Thoidis; A M Shneider
Journal:  Vaccine       Date:  2008-03-14       Impact factor: 3.641

7.  Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.

Authors:  Rosamund Chapman; Enid Shephard; Helen Stutz; Nicola Douglass; Vasan Sambandamurthy; Irene Garcia; Bernhard Ryffel; William Jacobs; Anna-Lise Williamson
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

8.  Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs.

Authors:  Lúcia de Paula; Célio L Silva; Daniela Carlos; Camila Matias-Peres; Carlos A Sorgi; Edson G Soares; Patrícia R M Souza; Carlos R Z Bladés; Fábio C S Galleti; Vânia L D Bonato; Eduardo D C Gonçalves; Erika V G Silva; Lúcia H Faccioli
Journal:  Genet Vaccines Ther       Date:  2007-01-24

Review 9.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.